drugset / Trial / NCT02386982
Beta Cell Function and Related Pharmacodynamics of HMS5552 in T2DM Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
This study evaluates the beta cell function, pharmacodynamics, pharmacokinetics, safety and tolerability after 4 weeks treatment of 75mgBID or 75mgQD of HMS5552.
Timeline
- Start
- 2015-03
- Primary completion
- 2015-05
- Completion
- 2015-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dorzagliatin | Small molecule | 75 mg | Oral |